Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 1/20 | 0.60 |
| ▸ | CA2 | P00918 | 1/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.57 |
| ▸ | HTT | P42858 | 1/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.57 |
| ▸ | MTNR1A | P48039 | 2/20 | 0.56 |
| ▸ | MTNR1B | P49286 | 2/20 | 0.56 |
| ▸ | USP2 | O75604 | 1/20 | 0.56 |
| ▸ | CTBP2 | P56545 | 1/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7355294 | 0.90 | MTNR1A (0.58) | CA1CA2ALDH1A1HTTSMN1; SMN2 | |
| SCHEMBL3199590 | 0.88 | MTNR1A (0.62) | ALDH1A1HTTSMN1; SMN2MTNR1AMTNR1B | |
| SCHEMBL3209903 | 0.86 | HPGD (0.52) | CA1CA2ALDH1A1SMN1; SMN2MTNR1A | |
| SCHEMBL11654998 | 0.86 | CA1 (0.77) | CA1CA2ALDH1A1HTTSMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL11659562 | 0.84 | CA1 (0.76) | CA1CA2ALDH1A1HTTSMN1; SMN2 | |
| Methane SCHEMBL9652380 | 0.84 | PTGS1 (0.65) | CA1CA2ALDH1A1HTTSMN1; SMN2 | |
| SCHEMBL4028224 | 0.83 | CA1 (0.70) | CA1CA2ALDH1A1SMN1; SMN2MTNR1A | |
| SCHEMBL28992026 | 0.83 | NPC1 (0.74) | ALDH1A1HTTSMN1; SMN2USP2POLB | |
| SCHEMBL3208992 | 0.82 | NPC1 (0.64) | CA1CA2ALDH1A1HTTSMN1; SMN2 | |
| SCHEMBL30639518 | 0.82 | KMT2A (0.65) | CA1CA2ALDH1A1MTNR1AMTNR1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102319184-B | Parakeratosis inhibitor, pore-shrinking agent and external composition for skin | SHISEIDO CO LTD | 2015-03-25 | — | — | CN | disclosed |
| US-8937090-B2 | Parakeratosis inhibitor, pore-shrinking agent and external composition for skin | SHISEIDO COMPANY, LTD. (JP) | 2015-01-20 | — | — | US | disclosed |
| US-20120232111-A1 | Parakeratosis inhibitor, pore -shrinking agent and external compositon for skin | SHISEIDO COMPANY, LTD. (JP) | 2012-09-13 | — | — | US | disclosed |
| US-20120165409-A1 | WRINKLE-IMPROVING AGENT | SHISEIDO COMPANY, LTD. (JP) | 2012-06-28 | — | — | US | disclosed |
| US-20100035881-A1 | WRINKLE-IMPROVING AGENT | SHISEIDO COMPANY, LTD. (JP) | 2010-02-11 | — | — | US | disclosed |
| EP-1941861-A1 | WRINKLE-IMPROVING AGENT | Shiseido Company, Limited (JP) | 2008-07-09 | — | — | EP | disclosed |
| EP-1880711-A1 | PARAKERATOSIS INHIBITOR, PORE-SHRINKING AGENT AND EXTERNAL COMPOSITION FOR SKIN | Shiseido Company, Limited (JP) | 2008-01-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100035881-A1 | WRINKLE-IMPROVING AGENT | AAAS, GLA, COL14A1 | CA1 4651/4885CA2 2941/4885ALDH1A1 1501/4885 |
| US-20120232111-A1 | Parakeratosis inhibitor, pore -shrinking agent and external compositon for skin | CUTA, AAAS, NUP160 | CA1 1466/4885CA2 876/4885ALDH1A1 3543/4885 |
| US-20120165409-A1 | WRINKLE-IMPROVING AGENT | AAAS, GLA, COL14A1 | CA1 4609/4885CA2 3261/4885ALDH1A1 1151/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.